News

Submitted proposals - HORIZON-CL3-2022-CS-01 (call closed on 16 November 2022)

Published on | 3 years ago

Programmes
Security

A total of 125 proposals has been submitted to the above mentioned call to the following topics: 

  • HORIZON-CL3-2022-CS-01-01 - Improved monitoring of threats, intrusion detection and response in complex and heterogeneous digital systems and infrastructures (IA) -  62 proposals
  • HORIZON-CL3-2022-CS-01-02 - Trustworthy methodologies, tools and data security “by design” for dynamic testing of potentially vulnerable, insecure hardware and software components (RIA) -  42 proposals
  • HORIZON-CL3-2022-CS-01-03 – Transition towards Quantum-Resistant Cryptography (IA) – 11 proposals
  • HORIZON-CL3-2022-CS-01-04 - Development and validation of processes and tools used for agile certification of ICT products, ICT services and ICT processes (IA) – 10 proposals

For all above mentioned proposals, the evaluation will be organized over the coming weeks and months.

Source: Funding and Tender Portal

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1802 articles available search in articles 

Testimonial

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.